Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Burundi has been steadily growing in recent years, driven by several factors such as increasing prevalence of hypertension and rising healthcare expenditures.
Customer preferences: Burundian customers tend to prioritize affordability and accessibility when it comes to healthcare products, including anti-hypertensive drugs. As a result, generic drugs are more popular than branded ones in the country. Additionally, many customers prefer to purchase their medications from local pharmacies or informal markets rather than hospitals or clinics.
Trends in the market: One major trend in the Burundian Anti-Hypertensive Drugs market is the increasing availability of low-cost generic drugs. This has been facilitated by the government's efforts to reduce drug prices and increase access to healthcare for the general population. Another trend is the growing awareness of hypertension and its associated health risks, which has led to more people seeking medical treatment and purchasing anti-hypertensive drugs.
Local special circumstances: Burundi is a low-income country with a relatively underdeveloped healthcare system. This presents challenges for the Anti-Hypertensive Drugs market, as many people cannot afford to pay for expensive medications or medical treatment. Additionally, the country has experienced political instability and conflict in recent years, which has further strained the healthcare system and limited access to medical resources.
Underlying macroeconomic factors: Burundi's economy is heavily reliant on agriculture, which accounts for over 90% of export earnings. This has led to a lack of diversification and vulnerability to external shocks such as droughts and fluctuations in commodity prices. The country also faces high levels of poverty and unemployment, which limits the purchasing power of many consumers. These macroeconomic factors contribute to the challenges faced by the Anti-Hypertensive Drugs market in Burundi.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
